Refining endpoints in brain tumor clinical trials Academic Article uri icon

Overview

MeSH Major

  • Brain Neoplasms
  • Clinical Trials as Topic
  • Endpoint Determination
  • Quality of Life
  • Research Design

abstract

  • As targeted therapies advance treatment for brain tumors, standard clinical trial endpoints of survival, progression free survival and radiographic response have become insufficient to capture clinical benefit. Brain cancer is a malignancy with neurodegenerative features. In this setting prolongation of life and/or radiographic stability are less clinically meaningful if neurocognitive function substantially declines. Hence evaluation of new therapeutic strategies should routinely include periodic assessment of neurocognitive function.

publication date

  • June 2012

Research

keywords

  • Academic Article

Identity

Language

  • eng

Digital Object Identifier (DOI)

  • 10.1007/s11060-012-0813-8

PubMed ID

  • 22451194

Additional Document Info

start page

  • 227

end page

  • 30

volume

  • 108

number

  • 2